Last reviewed · How we verify
NCT03641690: ARDS
Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
trial testing Empirical antimicrobial therapy in H1N1 Influenza in 97 participants. Completed in 1 December 2017.
1 December 2017
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire, Amiens |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 97 |
| Start date | 1 September 2013 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 December 2017 |
Drugs / interventions tested
- Empirical antimicrobial therapy
Conditions studied
- H1N1 Influenza — all drugs for H1N1 Influenza →
Sponsor
Centre Hospitalier Universitaire, Amiens
Who can join
18 and older, any sex, with H1N1 Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mannose-binding lectin (MBL) plays an important role in the innate immune response. In addition to activating the complement, MBL can induce cytokine production and contribute to a deleterious inflammatory response with severe A(H1N1)pdm09 virus infection. The aim was to determine if serum MBL levels correlate with the risk of mortality in intensive care units (ICU) patients with A(H1N1)pdm09 infection. Prospective observational study was performed in ICU patients with acute respiratory distress syndrome due to influenza A(H1N1)pdm09 virus. Demographic characteristics and severity indices were recorded at ICU admission. MBL was assayed from blood drawn at influenza diagnosis within 24-48 h following the ICU admission. Outcomes were compared according to MBL levels.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Complement as a vital nexus of the pathobiological connectome for acute respiratory distress syndrome: An emerging therapeutic target.
Yang Z, Nicholson SE, Cancio TS, Cancio LC, et al · · 2023 · cited 11× · PMID 37006238 · DOI 10.3389/fimmu.2023.1100461
Verify or expand the search:
- PubMed search for NCT03641690
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Universitaire, Amiens trials
Trials by the same sponsor.
- NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
- NCT07071662 — Induction of Labor in Breech Presentation · completed
- NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
- NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
- NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03641690 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 21 May 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
- Last refreshed: 17 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03641690.